Q2 2022 Eiger BioPharmaceuticals Inc Earnings Call
The conference will begin shortly to raise your hand during Q&A you can dial star one one.
[music].
Yes.
Yeah.
And business update conference call at this time, all participants are in a listen only mode.
Later, we will conduct a question and answer session and instructions will follow at that time, if anyone should require operator assistance. Please press Star then zero on your telephone.
As a reminder, this call will be recorded.
I would now like to introduce sorry, Madison Senior Vice President Corporate Affairs I agree you may begin.
Thank you.
Thank you for joining us today welcome to our quarterly financial results and business update call. We issued a press release earlier this afternoon with our Q2 financial results.
It's also available on our website either by an adult com.
For today's call, we will have to pass them off from the management team followed by Q&A.
The slides for the webcast and a replay will be available on the investor section of our website.
Joining me on the call with prepared remarks are they equally.
Should we be Ali Chief Financial Officer, Eldon Mayer, Chief Commercial officer, and adult English Senior Vice President of clinical development. We also have subject matter experts.
My opinion lots of Collins, senior Vice President clinical and development operation and off the call.
Craig Vice President metabolic diseases.
Right.
Before we begin I'd like to invite remind investors that this call will include forward looking statements, including expectations concerning financial performance commercial products and potential future products and get the therapeutic areas and stages of development. The forward looking statements rely on certain assumptions and involve risks and uncertainties beyond August .
All of which could cause actual results to differ materially.
These risks and uncertainties is contained in <unk> filings with the SEC, including our latest 10-K and 10-Q reports are available on the website in the investors section. All forward looking statements are based on information currently available to either and we assume no obligation to update these statements.
I'll now turn the call over to David.
Thanks Sarah.
As we enter the second half of 2022 momentum continues to build across all of our programs with multiple upcoming value creating milestones.
These clearly position <unk> as a highly differentiated biopharmaceutical company with a diverse pipeline.
With major catalysts in our development programs for Peg interferon Lambda loan upon it and <unk> as well as on the commercial front with no can be we believe that 2022 is shaping up to be a transformational year for <unk>.
I'll begin with progress on our peg interferon Lambda program for COVID-19.
Since we announced positive topline results from the phase III investigator sponsored together study in March our team has been actively engaged with the FDA on a potential emergency use authorization application and have provided responses to all of the agencies information requests during this time.
As we continue to see the rise of your variance, including <unk>. It is clear that while the COVID-19 ready evolving it continues to be a burden to the public health system and the need for more effective medicines persists.
That together study demonstrated that despite widespread vaccination.
Significant risk of morbidity and mortality from COVID-19.
Especially for vulnerable patient populations.
We believe peg interferon Lambda represents an effective one enzyme therapeutic that is potentially agnostic to the shifting variant landscape and that if authorized could play a meaningful role in the COVID-19 response.
Given the ongoing need making peg interferon lambda available to the health care community continues to be our priority.
In terms of commercial readiness, we have launch quantities to support the introduction of peg interferon Lambda should the FDA grant emergency use authorization.
And as previously communicated we are actively planning for expanded production capacity.
Turning now to our hepatitis Delta virus program, we continued to advance our HDD platform with Lauder, Barnet and peg interferon Lambda both in phase III.
We are actively preparing for top line data from the phase III deliver study of loan of <unk> based regimens by the end of this year, a significant upcoming milestone for <unk> and for patients with H D D.
As hepatitis Delta virus affecting over 12 million people worldwide.
Health care and economic burden is enormous.
Developing first in class therapies to treat this devastating disease.
The commercial opportunity in the U S and Europe alone is estimated to be more than $1 billion and we believe both loan upon it and peg interferon Lambda have real momentum in phase III, providing opportunities for significant long term value creation.
Ingrid who will provide more details on our continued progress in both of these phase III program shortly.
Now turning to our rare metabolic disease programs.
We are advancing <unk> into the phase III Registrational program for congenital hyperinsulinism.
But <unk> has been granted FDA breakthrough therapy designation and rare pediatric disease designation, making it eligible for a priority review voucher upon approval.
Of Exenatide is an exciting opportunity for ichor and most importantly has the potential to transform the lives of children born with this life threatening condition.
Now finally, turning to our commercial product we were delighted recently announced European approval of Zoe can be to treat children and young adults with Hutchinson Gilford Progeria syndrome, and processing deficient perjury landing apogees collectively known as progeria.
As the world's first and only treatment for Progeria, Joe Kennedy a European approval is an important milestone for the progeria community.
As <unk> first approval in Europe . This is also a significant achievement for our company, establishing our footprint in Europe , and demonstrating our ability to navigate ex U S regulatory requirements.
We're also expanding global commercial access through that it can be through strategic partnerships in countries like Japan.
Our recently announced partnership with Angelus.
Eldon will provide more details on our commercial progress in just a few moments.
This is an exciting time for either 2022 has already been successful as we've achieved key milestones, which further reinforces our confidence in our ability to execute and we're making great progress as we prepare for critical catalysts during the remaining half of this year.
We remain focused on our operational plan to drive growth by advancing our pipeline leveraging our commercial capabilities to expand our reach and strengthening the foundation of our business. The progress we have seen this year is reflected across all of these objectives.
Going forward, we will continue to leverage our internal capabilities and capitalize on our strengths in a cost efficient manner to position either for sustained growth I believe this will create value for our shareholders and fulfill unmet needs for patients with serious diseases in need of treatment options.
And now I'll hand, the call over to Ingrid to review, our clinical development progress. Thanks.
Thanks, David I'll begin by highlighting our progress across our HDD platform.
Hepatitis Delta virus system, a severe form of viral hepatitis, but the most rapid disease progression over half of patients are already cirrhotic at diagnosis.
We're on track to report topline data from the landmark phase III deliver study of two Luna final based regimens by the end of this year a significant milestone for ichor.
407 patients enrolled across 116 clinical trial sites in 22 countries deliver will generate the single largest source of HDD patient data from a well controlled clinical trial to better understand and characterize this devastating disease.
If positive deliver data will support global regulatory filings for two different lunar foreigner based regimens. The study includes an all arm of loan of foreign up this at the time of year and a combination arm with peg interferon alpha.
Each arm will be separately compared to placebo with a primary endpoint of a two log decline in HDD RNA plus normalization of the L. T. After 48 weeks of treatment.
Key secondary endpoints include histology.
Additionally, we are continuing to advance development of our second therapy for HBV peg interferon lambda into phase III limit to study.
Two is a randomized two arm study on one is 48 weeks of Lambda Once weekly followed by 24 weeks after treatment arm.
Arm two starts with 12 weeks of no treatment, followed by 48 weeks of treatment.
The primary endpoint is the proportion of patients with a durable Virologic response at 24 weeks post treatment in arm, one compare to 12 weeks of no treatment and onto.
This endpoint was previously demonstrated in our phase II and it's most meaningful for regulatory agencies and physicians as it demonstrates the durability of response to a finite therapy and a potential for an HBV cure.
When it too is a straightforward study of 150 patients where all patients will receive treatment, we're activating sites and enrolling patients in over 10 countries.
Our strategic approach in HDD is to seek regulatory approvals of two loan a foreigner based regimens from the results of the deliver study we will quickly follow the data for limited too, which could lead to approval of peg interferon Lambda for HBV.
We believe this approach provides the most expeditious route to approval for both loan of Farnell and Peg interferon Lambda.
In parallel we are generating data through the list two study, which we believe will support the future use of our proprietary combination of Luna Farnell and peg interferon Lambda for hepatitis Delta infection.
We are excited about the advancements that are being made in the HDD space. The first international Delta care conference. The only medical meetings focused solely on HDD epidemiology diagnosis and recent advancements in antiviral treatments is coming up in early October in Milan, Italy.
S O D will immediately follow in early November in Washington D C.
I hear it's contributing to the strong momentum with our HDD platform of multiple potential treatment options for patients we.
We believe <unk> is well positioned to become a leader in this space.
Finally, turning to <unk>, our first in class <unk> antagonist that we are developing as a targeted therapy for rare metabolic diseases.
We're excited to initiate the phase III advanced program for our lead indication congenital hyperinsulinism, a rare life threatening genetic disease with a devastating impact on newborns and children.
Our team has obtained alignment with the FDA on what we believe will be an efficient phase III clinical program and we look forward to sharing more details on the program as we begin screening patients later this year.
Additionally, we were encouraged by the positive response to phase III data recently presented at the Endo Conference in June .
These data support the broader potential of <unk> in the treatment of patients with hypoglycemia after bariatrics and other upper Gi surgeries further building on the role of <unk> in mediating hyper install anemic hypoglycemia.
I'll now hand, the call over to Eldon.
Thanks, Andrew.
I'll provide highlights of our activities to support hepatitis Delta virus commercial planning.
Well as an overview of our current can be business in the U S and our plans for expanding global access, including in Europe , where we just received marketing authorization from the European Commission.
In January we attended the Eagle International liver conference or either had a major program with multiple presentations highlighting data across our HDD platform.
There has been developing treatments for HDD and attending these conferences for over a decade, and we're encouraged to see hepatitis Delta featured more prominently than ever before.
Major liver conference.
The awareness of HDD is rapidly growing alongside the recognition that this is a serious disease and urgent need of therapies.
The competitive space is also growing in HCV with companies investing in early stage programs recognizing as global opportunity.
It is estimated to be over $1 billion in the U S and Europe alone.
One a part of and taken it for Atlanta, our late stage programs, which we believe are highly differentiated from other therapies in development.
<unk> is the only oral therapy in clinical development for HCV, and we expect that patient preference for a convenient oral HCV therapy will be high.
We also believe it is a first in class type three interferon peg interferon Lambda is tolerability profile will make it the interferon of choice for physicians and patients leading to better compliance and improved outcomes.
By the time, we launched one in front of it we expect increased awareness and diagnosis rates of hepatitis Delta virus made possible by greater utilization of commercial HBV Pcr tests.
And updates to Eagle and <unk> testing guidelines.
We look forward to attending additional conferences, including the <unk> liver meeting in November where we're planning to have a major presence.
Moving on to the <unk>, we reported $3 $3 million in net sales during the second quarter in the U S. As we've previously stated 80% of identified U S patients with progeria receives it can be with 100% payer reimbursement coverage.
Following the approval as it can be in Europe , we're moving at pace with our launch plans.
Appropriate infrastructure in place for successful commercialization across the EU, including distribution and patient support services.
We're engaged with health care providers, who are managing patients with progeria as well as the reimbursement authorities ministries of health and local payers to obtain reimbursement in each country.
There are approximately 20 identified patients across Europe and half of those are already receiving that can be through expanded access or clinical trials.
We're encouraged by the positive response to the kenzie from physicians across Europe marketing authorization in Europe is an important milestone both for either in the progeria community and we now look forward to bringing that can be the market to further support patients in need.
To summarize we're pleased with our commercial progress.
The infrastructure, we've established in the U S and now in Europe can scale and grow to support future launches in larger indications as we advance our mission to help patients with serious diseases.
I'll now hand, the call over to <unk> for a financial update.
Thanks Kelvin the press release, we issued this afternoon includes the financial update and I'll call out a few highlights here that demonstrate continued progress against our strategic and operational priorities.
Total revenue this quarter was $4 1 million, which included there can be sales net sales of $3 $3 million as Albert noted.
$750000 for a one time upfront payment related to our partnership with <unk>.
And just for there can be in Japan.
Turning to our second quarter 2022, GAAP operating expenses cost of sales was approximately zero point $2 million.
R&D expenses were $17 million and SG&A expenses were $7 million for the quarter.
You reported a second quarter net loss of $21 9 million.
Our 51 on a per share basis.
Our operating cash burn this quarter included a onetime $5 million payment to BMS related to our phase III limit to study a peg interferon lambda for HDD.
This is R&D expense in the first quarter and made the cash payment in the second quarter.
As we've discussed before a key part of our growth strategy is to develop and commercialize innovative therapies for underserved patients in a capital and resource efficient manner.
Our continued expense discipline and strong balance sheet provide us with operational flexibility and has allowed us to advance another program <unk> for congenital hyperinsulinism into phase III.
Presumably announced that we entered into a term loan agreement with Novartis capital partners.
This transaction allowed us to retire our previous debt facility and extend the interest only for five years.
We netted approximately $11 million at closing and importantly access up to an additional $35 million non dilutive capital based on specific clinical and regulatory milestones.
With approximately $142 million in cash cash equivalents and investments as of June 30, we are well positioned ahead of an important milestone for this year.
Expect this cash to fund planned operations through 2024.
I will now open up the call for Q&A operator, please provide the instructions for the Q&A portion of the call.
Thank you ladies and gentlemen, if you have a question at this time. Please press the star one one key on your touch phone telephone.
If your question has been answered or you wish to remove yourself from the queue. Please press the pound key.
Ask that you please limit yourself to one question and one follow up one moment for our questions.
And your first question comes from the line of Maury Raycroft of Jefferies. Please go ahead.
Congrats on the progress.
For Covid I was wondering if you can provide more perspective at this point into the nature of Fda's information request related to the Covid EUA application and are there more specifics on next steps that you can share.
Thanks, Marty I appreciate you joining the call and for your question I'll pass that to Ingrid.
Ari.
So as you know concurrent with the topline data that we announced in mid March that was when we also shared this topline date with FDA and since then we've been in active discussion with them together.
Together is a investigator sponsored study and as such it's necessitated some additional dialogue with FDA and request for information. So the timeline isn't entirely within our control. However, we are pleased that we've responded to all of the information requests from FDA.
Submitting the EUA as you know is either top priority and as such we've been preparing our EUA application in parallel with our FDA dialogue and we're prepared to submit once we have final FDA feedback.
Got it so it sounds like just as a follow up it sounds like next step is waiting for FDA feedback.
And then as far as the publication for the data goes is there a status update on where that stands.
As you know there was a ground rounds on July 29th by at the Mills and.
Jeffrey Glenn and they announced that they have submitted the manuscripts for peer review.
Plan is still to.
Uh huh.
Mr call at the time of EUA submission such that we can we view data with investors.
Got it okay that makes sense, okay. Thanks for taking my question.
Thank you so much.
And your next question comes from the line of Hugo <unk> of Citi. Please go ahead.
On for Yigal, Thanks for taking my questions.
Maybe just drilling down a little more on the last question.
Latest thinking that in terms.
A timeline for actually filing.
And based on your earlier comments in terms of ramping up production is it your expectation that youll still have about 300000 doses available by the end of the year for Covid or does that number may be higher now.
Thanks, very much for joining us and for your questions and I'll turn since it's a two part question I will turn the first question regarding EUA timelines to Ingrid.
Yes, again, I'll, just reiterate I mean, the EUA submission is our top priority and in <unk>.
To expedite that we've been working in parallel to prepare this EUA application as we continue our dialogue with FDA.
Such that we'll be prepared to submit once we have final FDA feedback.
We understand the desire for more details on the EUA submission process and again as was mentioned earlier, making land available for COVID-19 is our top priority.
I will just add to that we believe that together data are robust and compelling and represent a real world population that is highly generalizable to the U S population.
While we are unable at this point to provide specific details on the ongoing discussions with FDA, we very much look forward to providing near term updates on the program.
And secondly, with regard to manufacturing and procurement and quantities I'll turn that one to Sri to respond yes. So as you know we are developing lambda for HDD and have completed registration batches at our CMO and anticipation of the phase III program, which is ongoing in HDD, we do expect to have.
Up to 300000 doses available for potential launch and importantly that is separate from the supply required for ongoing hedged into clinical trials.
As David noted in his comments, we are planning and working on our plans for manufacturing Scaleup.
Okay, great maybe if I can sneak in one more.
Sure.
I was just thinking about the deliver readout towards the end of the year are you able to maybe give a little more color on the on the on the timelines involved maybe one of the last patient visit will be in the database lock and so on are you thinking that the readout might just be in December or is there a possibility it might be a little earlier, thanks very much.
Thanks, Yes, so we announced that we had completed enrollment of 407 patients back in November of last year topline data as 48 weeks post that last patient reaching week 48. So we've guided that we will release top line data for deliver at the end of this year, we haven't given any more granularity.
Beyond that but we are on track for deliver data by end of this year.
Okay, great. Thank you very much.
Thank you. So much. Your next question comes from the line of Brian scrutiny of Baird. Please go ahead and ask your question.
And on for Brian Thanks for taking our questions. Just a couple on the CACI Phase III program, we hosted a call a while back and he noted the importance of reductions in tube feedings Octreotide use.
And improved fasting period.
Key benefits that would be that you would be looking for in a therapeutic will any of these aspects should be touched on in the study endpoints.
Hey, Brian Thanks, so much for joining the call and for your questions and we were excited to announce a versatile beginning registration.
In congenital hyperinsulinism this year and Dr. Colleen Craig actually not only one of the inventors on the program, but also running the clinical program for US and has joined US for this call. So I'll turn those questions to Colleen.
Yes.
Ingrid and David described we're very pleased with the progress that we've made to date and initiating the phase III program.
And we do plan to disclose further details.
And endpoints.
As we begin to screen patients later this year.
What I can say at this point is that we worked very closely and collaboratively with <unk>.
Being a leader.
As well as the congenital hyperinsulinism patient advocacy organizations.
Regulator to craft.
Online on a thoughtful and efficient program that addresses the unmet medical need some of them.
You have raised with patients.
Hey, Brian .
We're pleased with the feedback we've received from stakeholders in it.
Progress we've made to date.
I'll just add.
We will go ahead Brian .
Oh No I was just go ahead go ahead.
We're just going to say we.
We are pleased to initiate the program this year and we believe it's a good thing for patients that this has become fairly competitive.
<unk> four agents in development of Therapeutics and development, we think of <unk> as a highly targeted mechanism is a <unk> antagonist and believe it's not only best in class that may be best in group.
We're targeting this severe disease and so we've been thoughtful about how much we communicate on the phase III study design, but clearly as we get closer to screening and enrolling our first patients will provide more guidance.
Great. So we can expect more details this year, if I'm understanding correctly or would that potentially be a 2023.
That is our plan.
Okay.
Great. Thanks.
Thank you so much. Our next question comes from the line of Robert Hazlett from BPI. Please go ahead and ask your question.
Yes, thanks for taking the question.
One or two on HDD kind of big picture questions actually with regard to HGV.
At your sense the testing maybe.
Maybe of HPV BV positive patients is increasing.
And then could you just give us maybe parameters with regard to how youre thinking about pricing of therapeutics in the category.
Sure I think those are good questions for clinical and commercial respectively, but maybe ill begin with Eldon, who can probably address both questions and thanks for the questions Eldon.
Yes, hi, Bert so we.
We've been monitoring the market and purchasing some data and we are gradually seeing increased levels of HPV testing of course.
We do expect that to continue to increase.
As products approach commercialization in the educational efforts and awareness efforts do increase.
So we'll continue to monitor that and we'll probably have more information for you on that in the future.
With respect to HDD pricing of course, there are no products available in the U S. At this time.
So there are no bench.
Benchmarks there in Europe . However.
We're monitoring that situation as well and we know that.
<unk> has been available for different prices and different markets.
That range between the $100000 range of a $150000 range just to give you a couple benchmarks there but of course as we get a closer look at our data and we're able to evaluate it and conduct some market research that will be able to understand the value proposition that our products will hold which we think will be very strong.
With what our products have to offer and we will be able to.
We have determined the appropriate price too.
The right access and the right value for the shareholders and the company. Thanks.
Thanks, Alan and Brian I'll, just add to that.
Eldon mentioned in his prepared remarks, we attended the Eagle International liver conference in London.
Two months ago, and I can tell you after being in this space now for 14 years. This liver conference had the greatest exposure for hepatitis Delta virus infection in my experience and we view that as very positive to directly answer. Your question. There is more attention being placed on HDD today then.
EVAR is forcing entrants in guidelines discussion by both <unk> and <unk> and we believe that will lead to more testing of HBV positive patients.
So we don't need to find these patients de novo, we only need to test HPV positive patients to find those patients who are contacted with delta and we believe that we're well on our way.
We believe that the competitive environment with multiple programs in development will also fuel that and support that activity.
That's good to hear thank you for all that just if I could slide in one financial question is was there any used the ATM post quarter.
Yes, we announced in our Q1 call a pro forma cash number that included ATM sales in April on there hasnt been any additional sales from the ATM other than what we announced back in our call in May.
Okay. Thank you for that congratulations on the progress reported the data.
Thank you.
Thank you and your next question comes from the line of.
Michael Higgins from Edwards. Please go ahead. Thanks, operator, thanks, guys. Thanks for taking my question.
We're certainly looking forward to deliver data around and just ahead of year end the way it looks.
Question for you could frame can host in the R&D events R&D day events.
Prior to that.
Sure Hey, Michael Thanks, so much for joining the call and for the thoughtful question, which is a good one I'll pass that industry has been talking about such an event tree Hey, Michael Yes, we are certainly looking at different ways going into deliver data too.
Spend some more time talking about our programs talking about HDD generally if you mentioned it will be at upcoming conferences and certainly around deliver data we would plan to host a call and talk through the details of that data, but stay tuned more to come as we finalize details.
Okay I appreciate that and then turning our attention to the opportunity in treating COVID-19 patients.
Can you share with us what groups you are talking to globally.
Whether that'd be in outside of the U S and Europe .
There may be buyers of your product.
And then there are groups that youre working with.
Thanks, Michael I'll tackle that question.
It's fair to say, we as discussed in our prepared remarks are very much on prioritizing and focused on an FDA.
<unk> to submit an EUA application and subsequently our plan is for an EUA authorization, we think that FDA stamp of approval is very important that being said we know that this is a global pandemic and we definitely had region as we've communicated previously from other regulators in other regions of the.
The World and we have plans to in next steps follow up and begin discussions with those other regulatory agencies.
Likewise, it's fair to say that we have been in discussions with potential collaborators and partners who have keen interest.
And have not communicated.
And that but believe that our first step in obtaining an emergency use authorization will catalyze many if not most of those discussions such that we'll be able to communicate progress in the future.
Okay, I appreciate that commentary and our intention to as it can be in Europe . If you can remind us the number of patients.
That you've identified there and your thoughts on the pace of adoption.
Obviously, you noted roughly half for just over half already on drug but also on the <unk>.
Pricing may look like in Europe versus the U S. Thanks.
Sure I'll turn that one over to our Chief commercial officer album sure.
So we have.
We have identified approximately 20 patients across Europe .
As you mentioned roughly approximately half of those are already on drug.
Either on a clinical trial or on.
Our managed access program.
The percentage of patients that were on these programs in the U S.
Higher so based on that and that reimbursement as you probably know can be more of a lengthy process in Europe and in the U S.
We would expect to get patients on commercial supply.
Over a longer time period, but in a steady fashion over the second half of this year in the first half of 2023.
And some.
And we're looking to convert them over that time period, as we're able to achieve reimbursement in various countries, which is done on a country by country basis.
With respect to.
Pricing.
Reimbursement is negotiated.
By country as I mentioned.
So we are engaged with the European authorities to file.
All the required dossiers that support access to drug which includes pricing and that will take some time, but we will share those details in the future.
More specific information becomes available.
I appreciate it thanks guys.
Thank you so much and again if you have a question. Please press star one one on your Touchtone telephone.
And im not showing any further questions I would now like to turn the call back to David <unk> for any further remarks.
Sure. Thank you so much.
I'd just like to close by reiterating the fact that it's been a quarter of successful delivery on here at either against our objectives and we're very excited to be driving forward to what we believe are multiple value, creating milestones very soon in the second half of this year and that we anticipate we will deliver.
Both patient and shareholder impact by continuing the execution that we've reported today I look forward to providing future updates on our progress across all of our programs, including what we believe will be near term updates on our peg interferon Lambda COVID-19, EUA submission plans and a.
Of course, none of it would be possible without our dedicated people and so I'd like to take this opportunity to thank the IR team for their relentless efforts across all of our programs and equally important. Thank all of you for taking the time and joining us today on our call. Thank you very much and have a great day.
Yeah.
The conference will begin shortly to raise your hand during Q&A you can dial one one.
[music].
Yeah.
Yes.
[music].
Sure.
Okay.
Okay.
[music].
Yes.
[music].
Okay.
[music].
Sure.
[music].
Yes.
Okay.
[music].
Yes.
Okay.
Okay.
Yes.
Okay.
Thank you.
Okay.
Okay.
Sure.
Okay.
Sure.
Okay.
Yes.
Yes.
Yes.
Yes.
Okay.
[music].
Yes.
Yes.
[music].
Sure.
Yes.
Okay.
[music].
Okay.
[music].
Okay.
Okay.
Okay.
Yes.
Okay.
Sure.
[music].
Okay.
Okay.
Okay.
Okay.
Yes.
Thank you.
Okay.
Okay.
[music].
Sure.
Yes.
Okay.
Okay.
Okay.
Thank you.
Yes.
Sure.
Yes.
Okay.
Sure.
Okay.
Yes.
[music].
Okay.
Okay.
Okay.
Thank you.
Yes.
Okay.
Okay.
Yes.
Yes.
Okay.
Sure.
Okay.
Okay.
[music].
Yes.
[music].
Yes.
Okay.
Yes.
Yes.
Okay.
Okay.
Okay.
Okay.
[music].
Yes.
Okay.
Sure.
Okay.
Yes.
[music].
Okay.
Okay.
Okay.
Yes.
Yes.
[music].
Yes.
Okay.
Yes.
Yes.
Okay.
Yes.
Okay.
Yes.
Sure.
Sure.
Yes.
Okay.
Yes.
Okay.
[music].
Sure.
Yes.
Sure.
Okay.
Yes.
Thank you.
Sure.
Okay.
Yes.
Okay.
Yes.
Sure.
Sure.
Okay.
Okay.
Okay.
Okay.
Right.
[music].
Yes.
Okay.
[music].
Yes.
Yes.
[music].
Okay.
Okay.
[music].
Yes.
Okay.
Okay.
Yes.
Okay.
Okay.
Yes.
Yes.
<unk>.
Okay.
Okay.
Yes.
[music].
Okay.
Okay.
Thanks.
Sure.
Okay.
Great.
Okay.
Sure.
Okay.
Yes.
Okay.
Okay.
Okay.
[music].
Okay.
Yes.
[music].
Yes.
Okay.
Okay.
Okay.
Yes.
Okay.
Yes.
[music].
Yes.
[music].
Yes.
Yes.
Okay.
Okay.
Yes.
Okay.
Yes.
Yes.
Sure.
Okay.
[music].
Yes.
Okay.
Yes.
Sure.
Okay.
Yes.
Yes.
Yes.
Okay.
Yes.
Okay.
Yes.
Yes.
Thanks.
Okay.
Yes.
Okay.
Yes.
[music].
Okay.
Yes.
Okay.
Okay.
Thank you.
Okay.
Yes.
Okay.
Okay.
Okay.
Yes.
Okay.
Okay.
Okay.
Yes.
Sure.
Yes.
Yes.
Yes.
Great.
Yes.
Okay.
Yes.
Yes.
Thank you.
Yes.
[music].
Yes.
[music].
Thank you.
[music].
Yes.
Yes.
Thank you.
Yes.
Okay.
Sure.
Okay.
Okay.
Yes.
Yes.
Great.
Okay.
Okay.
Okay.
Thank you.
Okay.
Okay.
[music].
Yes.
Yes.
Okay.
Okay.
Thank you.
Okay.
Okay.
Okay.
Yes.
Thank you.
Yes.
Yes.
Yes.
Yes.
Okay.
Yes.
Okay.
Sure.
Okay.
Okay.
Yes.
Okay.
Okay.
Okay.
Okay.
Okay.
Yes.
[music].
Okay.
Thanks.
Okay.
Sure.
Okay.
Okay.
Okay.
Okay.
Okay.
Okay.
Yes.
[music].
Okay.
Okay.
Yes.
Yes.
Yes.
Yes.
Okay.
Okay.
Okay.
Yes.
Yes.
Yes.
Great.
Okay.
Okay.
Yes.
Okay.
Yes.
Okay.
Okay.
Okay.
[music].
Okay.
Yes.
Okay.
Sure.
Okay.
Yes.
Okay.
Yes.
Okay.
Okay.
Yes.
Yes.
[music].
Yes.
Okay.
Okay.
Okay.
Okay.
Okay.
Sure.
[music].
Yes.
Okay.
[music].
Great.
Okay.
Sure.
Please.
Okay.
Okay.
Yes.
Okay.
Great.
Yes.
Sure.
Sure.
Right.
Okay.
Okay.
Okay.
Yes.
Okay.
<unk>.
[music].
Great.
Okay.
Thank you.
Yes.
Yes.
Okay.
Sure.
Sure.
Okay.
Sure.
Okay.
Yes.
Yes.
Yes.
Sure.
Okay.
Yes.
Okay.
Sure.
Thanks.
Okay.
Yes.
Okay.
Okay.
Yes.
Thanks.
Okay.
Yes.
Sure.
Okay.
Yes.
Okay.
Okay.
Yes.
Okay.
Sure.
Yes.
Yeah.
[music].
Yes.
Thank you.
[music].
Okay.
Okay.
Yes.